Christy L. Shaffer
General Partner @ Hatteras Venture Partners
Raleigh, United States
Christy L. Shaffer is a General Partner at Hatteras Venture Partners and was a President and CEO at Inspire Pharmaceuticals. She attended The University of Tennessee Health Science Center.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Christy L. Shaffer invests in
Stages Christy L. Shaffer invests in
Countries Christy L. Shaffer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (45%)
- Therapeutics 5 (45%)
- Biotechnology 5 (45%)
- Medical 3 (27%)
- Pharmaceutical 2 (18%)
Stage
- Series A 5 (45%)
- Series B 3 (27%)
- Series C 2 (18%)
- Angel 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina. | $5M / Series B / Apr 08, 2026 | ||
| Aer Therapeutics is a clinical-stage biopharmaceutical company that develops an approach to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis, and asthma. | $36M / Series A / Apr 13, 2023 | ||
| Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and causea significant amount of preventable blindness throughout the world.Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering.The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition. | $28M / Series A / Dec 01, 2021 | ||
| GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and itsown therapeutic products for major ocular disease indications including wet AMD and Glaucoma.The company was founded in 2011 and headquartered in Baltimore, Maryland. | $80M / Series C / Aug 20, 2019 | ||
| G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $47M / Series C / May 11, 2016 | ||
| GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and itsown therapeutic products for major ocular disease indications including wet AMD and Glaucoma.The company was founded in 2011 and headquartered in Baltimore, Maryland. | $44.5M / Series B / May 02, 2016 | ||
| Spyryx Biosciences develops a next-generation therapeutics for obstructive lung diseases.Spyryx Biosciences was formed in 2013 by our scientific founder, Dr. Robert Tarran, based on his discovery of a previously unknown mechanism that the lung uses to regulate fluid on its surface. This mechanism is dysfunctional in the lungs of CF patients dueto genetic mutations and is believed to be the root cause of the progressive dehydration that leads to the unfortunate cycle of mucus accumulation, bacterial colonization, immune response and tissue scarring, loss of lung function, and often early death. Spyryx's product leverages the mechanism discovered by Dr. Tarran and has shown promising results in preclinical studies by dramatically increasing survival in an animal model of CF. Their product's action is independent of the genetic mutations that cause CF, thereby having the potential to provide disease-modifying therapy to the entire CF patient population.Dr. Tarran's laboratory has also demonstrated a connection between this fluid regulation mechanism and the dehydration seen in COPD patients, who suffer from severe, chronic bronchitis and emphysema. Spyryx is investigating the application of its product to this devastating disease as well. | $18.2M / Series A / May 07, 2015 | ||
| GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and itsown therapeutic products for major ocular disease indications including wet AMD and Glaucoma.The company was founded in 2011 and headquartered in Baltimore, Maryland. | $1.7M / Series A / Mar 06, 2015 | ||
| G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $33M / Series B / Feb 05, 2015 | ||
| EvoApp makes analyzing big data easy by finding the patterns in relevant conversations that impact business decisions.Their real-time data mining and analysis platform gives big data meaning by correlating with metrics that drive businesses. They’ve helped customers quadruple lead generation, dramatically improve customer service, find thelanguage that makes them six times more relevant to their target audience and accelerate product launches.Connecting big data with business metrics provides new and better ways to answer the questions critical to success. EvoApp makes big data actionable with a scalable analysis platform previously only available to the largest institutions. They make big data approachable with solutions for every day users. EvoApp was founded by two NCSSM alumni, Joe Davy and Alexey Melnichenko in May 2009. | Series A / Jan 31, 2011 | ||
| See all 11 investments → | |||
Co-Investors
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Hatteras Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Douglas Reed
General Partner
|
|||
Jeff Terrell
General Partner
|
|||
Myla Lai-Goldman
Venture Partner
|
|||
|
Christy L. Shaffer
General Partner
|
|||
Clay B. Thorp
General Partner and Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christy L. Shaffer invest in?
Christy L. Shaffer invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Christy L. Shaffer?
Public channels for Christy L. Shaffer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christy L. Shaffer last invest?
The most recent investment recorded for Christy L. Shaffer closed in Apr 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
